India, April 1 -- Johnson & Johnson (JNJ) announced that following the approval of its pending acquisition of Intra-Cellular Therapies by Intra-Cellular Therapies' shareholders on March 27, 2025, Johnson & Johnson plans to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025.
The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by about 0.8% with approximately $0.7 billion in incremental sales.
Johnson & Johnson expects the transaction to adjusted earnings per share by about $0.25 in 2025, an improvement from the $0.30 - $0.35 originally estimated on the Company's fourth quarter 2024 earnings call. In 2026, Johnson & Johnson expects the earnings dilution to be reduced to approximatel...